Compare Inovio Pharmaceuticals Inc (INO) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Invesco Preferred ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Invesco Preferred ETF trades at $10.79. Which is the better fit depends on your goals.
| INO | PGX | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | — |
52-Week High | $2.87 | $11.87 |
52-Week Low | $1.05 | $10.81 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
PGX trades at $10.79, down 0.64% on the day, with a bearish technical outlook from moving averages. The ETF shows neutral momentum oscillators. Recent corporate actions include scheduled dividends for mid-2026. News highlights institutional selling and concerns over the fund's risk-return profile in the preferred stock space.
The outlook remains cautious due to structural subordination risks and interest rate sensitivity. Analyst sentiment is negative, citing capped upside and full participation in downturns. Key risks include credit defaults and macroeconomic shifts affecting preferred securities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
